Wuhan HHD Supply Dapagliflozin API The Novel Antidiabetic Drug
Dapagliflozin (ForxigaTM) is a new type of anti-diabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, which was approved by the European Medicines Agency (EMA) on November 12, 2012. The first SGLT2 inhibitor approved for the treatment of type 2 diabetes, which can be used as an important option in the treatment of diabetes drugs and can be used as a supplementary diet and exercise to improve blood sugar control in adults with type 2 diabetes. Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. The U.S. Food and Drug Administration (FDA) announced on January 8, 2014 Chemicalbook that it approved the use of Dapagliflozin for the treatment of type 2 diabetes. Manufacturers are also required to conduct post-marketing studies on drug-related risks. Postmarketing trials required by the FDA include a cardiovascular outcomes trial to assess cardiovascular risk in patients at high risk for cardiovascular disease at baseline after treatment with dapagliflozin and a study to assess bladder cancer risk in recruited patients. Another study will evaluate the drug's bladder tumor-promoting effect in rodents. Two studies will evaluate the pharmacokinetics, efficacy and safety of dapagliflozin in pediatric patients; an enhanced pharmacovigilance program will monitor liver abnormalities and reports of pregnancy outcomes in patients receiving dapagliflozin.
Uses:
A novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
Audited Supplier 
){kind=link}